|
BioAsia 2026 to catalyze global investments & accelerating innovation through AI-enabled drug discovery
|
|
Nandita Vijayasimha, Bengaluru
February 18 , 2026
|
|
|
BioAsia 2026 in its 23rd edition in Hyderabad is positioned as a pivotal platform for catalyzing global investments and accelerating innovation through artificial intelligence-enabled drug discovery. The two-day event from February 17 to 18 at HITEX was kicked off by convening pharmaceutical leaders, biotech startups, research institutions, and international investors.
Sachin Marihal, VP-BD/strategy, SasPinjaraLife Sciences told Pharmabiz on the sidelines of the event that with Hyderabad’s Genome Valley strengthening its position as a premier life sciences hub, Bio Asia is expected to foster strategic collaborations, unlock new funding avenues, and reinforce India’s growing leadership in next-generation healthcare innovation. Every year during BioAsia, multinational companies announce billions of dollars in investments for Telangana, reinforcing the state’s position as a premier global life sciences and biotech hub.
Here the Belagavi-based SasPinjara Life Sciences, the technical and business consultation provider for pharma and biotech in the global market is marking its presence at BioAsia 2026 to expand strategic partnerships and showcase its end-to-end capabilities. The company aims to engage with pharma and biotech innovators, manufacturers, investors, and research organizations to explore collaborative opportunities across drug development, regulatory strategy, technology transfer, and market expansion. By participating in the summit’s investment and AI-driven innovation dialogues, the company is positioning itself to support emerging and established pharma and biotech players in navigating complex global markets while accelerating R&D efficiency and commercialization pathways, said Aravind P, chief technical officer, SaSPinjara Life Sciences.
On a similar note, Anilkumar Ranadev, CSO, SasPinjara Life Sciences, said, “As India continues to strengthen its position as both the Pharmacy of the World and a rising innovation hub, we look forward to engaging with industry leaders, researchers, and decision-makers to drive the next wave of pharmaceutical transformation”.
Saspinjara is exhibiting its two pharma intelligence tools. One is Pharmacodia Global database which helps make decisions based on dynamic big data. The second is CYBER AIDD which is a real word data driven early phase drug discovery. These digital tools accelerate innovation and research, said Aravind and Ranadev.
Since the summit will spotlight how AI is transforming every stage of the R&D value chain from target identification and molecule design to clinical trial optimization, both Pharmacodia Global and Cyber-AIDD will take centre-stage at our Booth-P32, said Marihal.
This edition of BioAsia will also emphasize the TechBio which is at an inflection point. The fusion of biology and technology is redefining how we understand, diagnose, and treat disease. Hyderabad continues to lead with its innovation ecosystem, world-class infrastructure and strong collaborative spirit, bringing together biotechnology excellence and digital capability where biology meets AI, added Ranadev.
In an era marked by unprecedented global health challenges, the urgency for innovation, collaboration, and accelerated transformation in healthcare has never been greater. For Saspinjara, BioAsia gives unparalleled opportunity to meet with industry experts in life science and health tech, venture capitalists (VCs) and Angel investors, corporate M&A heads, access to conferences and networking, said Aravind.
|
|
|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|